为您找到相关结果约117个

你是不是要搜索 期刊Satralizumab 点击跳转

Satralizumab: First Approval

Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

EFFICACY OF SATRALIZUMAB THERAPY IN THE TREATMENT OF NMOSD

Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders

Urosepsis Risk in Neuromyelitis Optica Spectrum Disorder Patients Administered Satralizumab

Satralizumab: First Approval (Sep, 10.1007/s40265-020-01380-2, 2020)

Long-term safety of satralizumab in NMOSD

Satralizumab, Novel Interleukine-6 Inhibitor for Preventing Descending Thoracic Aorta Aneurysm Development

Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum

Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and

Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum

Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From

Satralizumab might not be enough. Olamkicept (sgp130Fc) in Neuromyelitis Optica Spectrum Disorder

Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient-Commentary

为您找到相关结果约117个

共117条页码: 1/8页15条/页